Jennifer Johnson
Family · Bakersfield, CANPI 1164920260
Payments from drug & device makers
Across 132 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$808
- Sanofi-aventis U.S. LLC$437
- Boehringer Ingelheim$413
- Bayer$376
- Medtronic$294
- Abbott$155
- plus $881 from 14 others
What the payments were for
- Food & beverage$3,34599%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 38 | $808 |
| Sanofi-aventis U.S. LLC | 20 | $437 |
| Boehringer Ingelheim | 14 | $413 |
| Bayer | 14 | $376 |
| Medtronic | 7 | $294 |
| Abbott | 4 | $155 |
| Novartis | 6 | $142 |
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| Dexcom, Inc. | 3 | $92 |
| Mannkind Corporation | 4 | $78 |
| AbbVie | 3 | $64 |
| Recordati_rare_diseases_inc. | 3 | $55 |
| Lilly USA, LLC | 3 | $52 |
| Novo Nordisk | 3 | $52 |
| Insulet Corporation | 2 | $45 |
| Ascensia Diabetes Care US Inc. | 2 | $45 |
| Echosens North America, Inc. | 1 | $40 |
| Amarin Pharma, Inc. | 2 | $39 |
| Merck | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$135
- Kerendia$100
How this compares
$3,364 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,253 | $1,361,537 |
| MounjaroTirzepatide | 334 | $358,437 |
| TrulicityDulaglutide | 300 | $338,856 |
| JardianceEmpagliflozin | 356 | $309,650 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 403 | $304,124 |
| FarxigaDapagliflozin Propanediol | 284 | $210,015 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 104 | $189,177 |
| Xigduo XrDapaglifloz Propaned/Metformin | 197 | $146,895 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 190 | $131,688 |
| Tresiba Flextouch U-100Insulin Degludec | 156 | $96,337 |
| Gvoke Hypopen 2-PackGlucagon | 69 | $67,330 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $63,554 |
| LyumjevInsulin Lispro-Aabc | 62 | $60,102 |
| RybelsusSemaglutide | 57 | $58,832 |
| Repatha SureclickEvolocumab | 68 | $56,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $52 | $1,450,3741,429 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $52 | $798,981940 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $413 | $654,911810 claims |
| AstraZenecaFarxiga | $808 | $210,015284 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $437 | $52,80255 claims |
| BayerKerendia | $376 | $47,68663 claims |
| MerckJanuvia | $22 | $28,76338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Bakersfield
- Jennifer TougasBakersfield$302K
- Ashton ChaseBakersfield$86K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.